¼¼°èÀÇ È£Èí±â Áúȯ¿ë AI ½ÃÀå º¸°í¼­(2025³â)
Artificial Intelligence (AI) In Respiratory Diseases Global Market Report 2025
»óǰÄÚµå : 1824583
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,457,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,334,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,211,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

È£Èí±â Áúȯ¿ë AI ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ¾ÈÁ¤µÈ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. 2029³â¿¡´Â CAGR 5.0%¸¦ ³ªÅ¸³» 97¾ï ´Þ·¯·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡, Á¶±â ¹ß°ß¡¤Áø´ÜÀÇ ¿ä±¸ Áõ°¡, ȯ°æ ¿À¿° È®´ë, ÇコÄɾî ÁöÃâ Áõ°¡, ¿¬±¸°³¹ß ÀÌ´Ï¼ÅÆ¼ºê¿¡ ±âÀÎÇÑ´Ù°í »ý°¢µË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ±â¼ú Áøº¸, ½Å¾à °³¹ß ¹× °³¹ß, °³ÀÎÈ­ Ä¡·á °èȹ, ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ µîÀÌ ÀÖ½À´Ï´Ù.

ÇâÈÄ 5³â°£ÀÇ ¼ºÀå·ü 5.0%¶ó°í ÇÏ´Â ¿¹ÃøÀº Àüȸ ¿¹ÃøÀ¸·ÎºÎÅÍ 0.2%ÀÇ ¼ÒÆøÀÇ °¨¼Ò¸¦ ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ÀÌ °¨¼Ò´Â ÁÖ·Î ¹Ì±¹°ú ´Ù¸¥ ±¹°¡ °£ÀÇ °ü¼¼ÀÇ ¿µÇâ ¶§¹®ÀÔ´Ï´Ù. ¹«¿ª ¸¶ÂûÀº À̽º¶ó¿¤°ú µ¶ÀÏ¿¡¼­ °³¹ßµÈ ÀΰøÁö´É(AI) ´ëÀÀ ½ºÆÄÀÌ·Î¸ÞÆ®¸® ±â±â¿Í ±âħ ÆÐÅÏ ÀÎ½Ä ¼ÒÇÁÆ®¿þ¾îÀÇ °¡°ÝÀ» ´Ã·Á COPD/õ½Ä °³ÀÔ Áö¿¬°ú È£Èí±â Ŭ¸®´ÐÀÇ ºñ¿ë »ó½ÂÀ» ÃÊ·¡ÇÔÀ¸·Î½á ¹Ì±¹ÀÇ Æó ÀǷḦ ÀúÇØÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ »óÈ£ °ü¼¼¿Í ¹«¿ª ±äÀå Áõ°¡¿Í Á¦ÇÑÀ¸·Î ÀÎÇÑ ¼¼°è °æÁ¦¿Í ¹«¿ª¿¡ ´ëÇÑ ¾Ç¿µÇâÀ¸·Î ÀÎÇØ ±× ¿µÇâÀÌ ´õ ±¤¹üÀ§ÇÏ°Ô ´Ã¾î³¯ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ȯ°æ¿À¿°ÀÇ È®´ë´Â ¾ÕÀ¸·Î ¼ö³â°£ È£Èí±â Áúȯ ½ÃÀå¿¡¼­ ÀΰøÁö´É(AI)ÀÇ ¼ºÀåÀ» Å©°Ô ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ȯ°æ¿¡ ´ëÇÑ À¯ÇØ ¹°Áú°ú ¿¡³ÊÁöÀÇ ¹æÃâÀ» Æ÷ÇÔÇÑ È¯°æ ¿À¿°Àº ´Ù¾çÇÑ È£Èí±â ½Ã½ºÅÛÀÇ °Ç°­ ¹®Á¦ÀÇ ¿øÀÎÀÌ µÇ¾ú½À´Ï´Ù. AI´Â ½Ç½Ã°£ ¸ð´ÏÅ͸µ, °³ÀÎÈ­µÈ À§Çè Æò°¡, °í±Þ ÀÇ»ç°áÁ¤ µµ±¸¸¦ ÅëÇØ ȯ°æ ¿À¿°ÀÌ È£Èí±â °Ç°­¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ¿¡³ÊÁö Á¤º¸±¹¿¡ µû¸£¸é CO2 ¹èÃâ·®Àº 2021³â 357¾ï 2,000¸¸ Åæ¿¡¼­ 2022³â 385¾ï ÅæÀ¸·Î Áõ°¡ÇÏ¿© ȯ°æ ¿À¿° ¼öÁØ »ó½ÂÀ» µÞ¹ÞħÇß½À´Ï´Ù. ¿À¿°ÀÌ È£Èí±â °Ç°­¿¡ ¹ÌÄ¡´Â ¿µÇâÀÌ °­È­µÊ¿¡ µû¶ó È£Èí±â Áúȯ¿ë AIÀÇ Ã¤¿ëÀÌ °¡¼ÓÈ­µÇ°í ¿À¿°°ú °ü·ÃµÈ °Ç°­ À§ÇèÀ» ´õ Àß °ü¸®ÇÏ°í ¿¹¹æÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Artificial intelligence (AI) in the context of respiratory diseases involves leveraging AI and machine learning techniques to assist healthcare professionals in diagnosing, managing, and treating various respiratory conditions. This technology holds significant potential across pulmonary medicine, offering applications in image analysis, predictive modeling, and disease management.

The primary imaging modalities in artificial intelligence (AI) for respiratory diseases include magnetic resonance imaging (MRI), computed tomography (CT) scans, and electronic patient-reported outcomes (ePRO). In the realm of chronic obstructive pulmonary disease (COPD), AI is applied to aid in the diagnosis, management, and treatment of this condition. Its applications extend to various indications such as chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary infections. These AI technologies find utilization in diverse healthcare settings, including hospitals, diagnostic centers, ambulatory surgical centers, and other medical facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The artificial intelligence (AI) respiratory disease market research report is one of a series of new reports from The Business Research Company that provides artificial intelligence (AI) respiratory disease market statistics, including artificial intelligence (AI) respiratory disease industry global market size, regional shares, competitors with an artificial intelligence (AI) respiratory disease market share, detailed artificial intelligence (AI) respiratory disease market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) respiratory disease industry. This artificial intelligence (AI) respiratory disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The artificial intelligence (AI) in respiratory diseases market size has grown steadily in recent years. It will grow from $7.66 billion in 2024 to $7.98 billion in 2025 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to increasing government regulations, growing environmental concerns, increasing aging population, growing patient-centric healthcare approaches, rise in healthcare infrastructure development.

The artificial intelligence (AI) in respiratory diseases market size is expected to see steady growth in the next few years. It will grow to $9.7 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to increasing prevalence of respiratory diseases, rising need for early detection and diagnosis, growing environmental pollution, rising healthcare expenditure, research and development initiatives. Major trends in the forecast period include technological advancements, drug discovery and development, personalized treatment plans, telemedicine and remote patient monitoring, remote patient monitoring.

The forecast of 5.0% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. pulmonary care by inflating prices of Artificial intelligence(AI)-enabled spirometry devices and cough pattern recognition software developed in Israel and Germany, resulting in delayed COPD/asthma interventions and higher respiratory clinic costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Growing environmental pollution is expected to significantly drive the growth of artificial intelligence (AI) in the respiratory disease market in the coming years. Environmental pollution, including the release of harmful substances and energy into the environment, contributes to various respiratory health issues. AI has the potential to mitigate the impact of environmental pollution on respiratory health through real-time monitoring, personalized risk assessments, and advanced decision-making tools. For instance, according to the US Energy Information Administration, CO2 emissions increased from 35.72 billion metric tons in 2021 to 38.50 billion metric tons in 2022, underscoring the rising environmental pollution levels. As the effects of pollution on respiratory health intensify, the adoption of AI in the respiratory disease market is expected to accelerate, enabling better management and prevention of pollution-related health risks.

Key players in the artificial intelligence (AI) segment of the respiratory diseases market are innovating with products such as N-Tidal devices designed to monitor patients' tidal breathing patterns. The N-Tidal device measures the volume of air exchanged during normal breathing, providing crucial insights into lung function. For instance, in August 2023, TidalSense, a UK-based respiratory technology company, introduced N-Tidal, an AI-regulated technology tailored for the diagnosis and management of chronic obstructive pulmonary disease (COPD). This technology integrates N-Tidal's CO2 sensor data with an AI platform to track changes in lung function, enhancing COPD diagnosis and management. Clinical studies have demonstrated the technology's high accuracy, promising to revolutionize the diagnostic process for respiratory ailments. The launch represents a significant milestone in leveraging AI for respiratory disease assessment, offering a more convenient and efficient alternative to traditional diagnostic methodologies.

In July 2023, ResMed Inc., a prominent US-based medical equipment provider renowned for its cloud-connectable medical devices, finalized the acquisition of Somnoware for an undisclosed sum. This strategic move bolsters ResMed's portfolio in sleep and respiratory care while synergizing with its current suite of digital respiratory healthcare solutions. The acquisition is poised to elevate patient care by optimizing the management of patient data, streamlining equipment ordering, scheduling appointments, and monitoring compliance. Ultimately, these enhancements are expected to elevate patient experience and health outcomes. Somnoware, a US-based cloud platform, specializes in advanced respiratory care management and hospital-at-home solutions, aligning seamlessly with ResMed's commitment to innovation and excellence in healthcare.

Major companies operating in the artificial intelligence (AI) in respiratory diseases market report are Siemens Healthineers, Philips Healthcare, General Electric (GE) Healthcare, Verily Life Sciences LLC, DeepMind Health, Merative L.P., Innovaccer, Freenome, Aidoc Medical, Butterfly Network, Infervision, Imagen Technologies, Caption Health, Gauss Surgical Inc., Swaasa AI, Inspirata Inc., VIDA Diagnostics Inc., Enlitic, Thirona B.v., ArtiQ, Icometrix, Zynnon AG, Aidence, Arterys, Dectrocel Healthcare, PneumoWave Ltd.

North America was the largest region in the artificial Intelligence (AI) in respiratory diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (ai) in respiratory diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the artificial intelligence (ai) in respiratory diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The artificial Intelligence (AI) in respiratory diseases market includes revenues earned by entities by providing services such as AI-assisted imaging analysis, digital pathology platforms, and AI-powered rehabilitation programs. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The AI in respiratory diseases market also includes sales IoT devices, wearables, and smart inhalers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Artificial Intelligence (AI) In Respiratory Diseases Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on artificial intelligence (ai) in respiratory diseases market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for artificial intelligence (ai) in respiratory diseases ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The artificial intelligence (ai) in respiratory diseases market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Artificial Intelligence (AI) In Respiratory Diseases Market Characteristics

3. Artificial Intelligence (AI) In Respiratory Diseases Market Trends And Strategies

4. Artificial Intelligence (AI) In Respiratory Diseases Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Artificial Intelligence (AI) In Respiratory Diseases Growth Analysis And Strategic Analysis Framework

6. Artificial Intelligence (AI) In Respiratory Diseases Market Segmentation

7. Artificial Intelligence (AI) In Respiratory Diseases Market Regional And Country Analysis

8. Asia-Pacific Artificial Intelligence (AI) In Respiratory Diseases Market

9. China Artificial Intelligence (AI) In Respiratory Diseases Market

10. India Artificial Intelligence (AI) In Respiratory Diseases Market

11. Japan Artificial Intelligence (AI) In Respiratory Diseases Market

12. Australia Artificial Intelligence (AI) In Respiratory Diseases Market

13. Indonesia Artificial Intelligence (AI) In Respiratory Diseases Market

14. South Korea Artificial Intelligence (AI) In Respiratory Diseases Market

15. Western Europe Artificial Intelligence (AI) In Respiratory Diseases Market

16. UK Artificial Intelligence (AI) In Respiratory Diseases Market

17. Germany Artificial Intelligence (AI) In Respiratory Diseases Market

18. France Artificial Intelligence (AI) In Respiratory Diseases Market

19. Italy Artificial Intelligence (AI) In Respiratory Diseases Market

20. Spain Artificial Intelligence (AI) In Respiratory Diseases Market

21. Eastern Europe Artificial Intelligence (AI) In Respiratory Diseases Market

22. Russia Artificial Intelligence (AI) In Respiratory Diseases Market

23. North America Artificial Intelligence (AI) In Respiratory Diseases Market

24. USA Artificial Intelligence (AI) In Respiratory Diseases Market

25. Canada Artificial Intelligence (AI) In Respiratory Diseases Market

26. South America Artificial Intelligence (AI) In Respiratory Diseases Market

27. Brazil Artificial Intelligence (AI) In Respiratory Diseases Market

28. Middle East Artificial Intelligence (AI) In Respiratory Diseases Market

29. Africa Artificial Intelligence (AI) In Respiratory Diseases Market

30. Artificial Intelligence (AI) In Respiratory Diseases Market Competitive Landscape And Company Profiles

31. Artificial Intelligence (AI) In Respiratory Diseases Market Other Major And Innovative Companies

32. Global Artificial Intelligence (AI) In Respiratory Diseases Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Artificial Intelligence (AI) In Respiratory Diseases Market

34. Recent Developments In The Artificial Intelligence (AI) In Respiratory Diseases Market

35. Artificial Intelligence (AI) In Respiratory Diseases Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â